1Glassock RJ. Reclassification of lupus glomerulonephritis: back to the future. J Am Soc Nephrol, 2004, 15: 501-503.
2Pollak VE, Pirani CL, Schwartz FD. The natural history of the reual manifestations of systemic lupus erythematosus. J Lab Clin Med, 1964, 63: 537-550.
3Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. New Engl J Med, 2000, 343: 1156-1162.
4Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. New Engl J Med, 2004,350: 971-980.
5Weening JJ, D′Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited.Kidney International, 2004, 65: 521-530.
6Austin HA Ⅲ, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. New Engl J Med, 1986, 314: 614-619.
7Balow JE, Austin HA Ⅲ Maintenance therapy for lupus nephritis: something old, something new. New Engl J Med, 2004,350:1044-1046.
10Naito T.Optimal immunosuppressive therapy based on pharmacokinetics and pharmacodynamics of antimetabolites in clinical practice. Yakugaku Zasshi . 2010
